CNMDNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31

CONMED Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026

$46.05−0.67 (-1.43%)

Close on Oct 19, 2026

Market cap: $1.39B
P/E (TTM): 24.9
Dividend yield: 1.30%

Fundamental chart

Pick a measure to chart its full history

$1.37BFY2025, +4.7% a year since FY2011

Where these numbers come from

Parsed from the XBRL in Conmed's annual and quarterly filings with the SEC
Per-share figures adjusted for the 3-for-2 split on Sep 10, 2001
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CNMD.

Revenue growth3.4% · median 4.9%

Gross margin55.8% · median 59.0%

Operating margin8.0% · median 9.7%

Net margin4.1% · median 7.0%

Company	Revenue	Growth
ENOV	$2.30B	+4.9%
TFX	$2.25B	+30.7%
ITGR	$1.84B	+2.7%
LIVN	$1.47B	+12.4%
CNMD	$1.37B	+3.4%
HAE	$1.35B	+0.4%

Company

Next earnings (est.): Nov 4, 2026, during market hours
Exchange: NYSE
Industry: Electromedical & Electrotherapeutic Apparatus
Fiscal year ends: December 31
Employees: 3,900
Held by institutions: 100.0%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 816956

Advertisement
300 × 250